28Jul 2022
Therapeutic potential of recombinant human basic fibroblast growth factor on postoperative patients with chronic rhinosinusitis with nasal polyps

Therapeutic potential of recombinant human basic fibroblast growth factor on postoperative patients with chronic rhinosinusitis with nasal polyps

To explore the effect of intranasal administration of recombinant human basic fibroblast growth factor (rh‐bFGF) on postoperative chronic rhinosinusitis with nasal polyps (CRSwNP) patients. Seventy‐five patients with CRSwNP were randomly assigned to three groups, and 72 completed the 1‐month medication regimen and 1‐year follow‐up. Rh‐bFGF nasal spray and drop application reduced general nasal VAS scores within 2 weeks after endoscopic sinus surgery (ESS) compared to the control group. Rh‐bFGF nasal drops and sprays can quickly and effectively relieve postoperative symptoms and improve the long‐term prognosis of patients with CRSwNP. Moreover, rh‐bFGF nasal drops are also effective for postoperative patients with eosinophilic CRSwNP.

  • #ent

Like

Save

Share